Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXP900 in Combination With Lorlatinib in Advanced ALK-positive NSCLC
NCT07784959Phase 1Recruiting
- Sponsor
- Nuvectis Pharma, Inc.
- Start
- Aug 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NXP900 in non-small cell lung cancer (NSCLC), sponsored by Nuvectis Pharma, Inc. Primary endpoints: Adverse Events at 30 days, Objective Response Rate at 12 months and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
NXP900
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07784959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784959.